Medical School · Year 3 · Obgyn · includes a quiz and discussion video

Seminar 19: Gynecologic Oncology

OB/GYN Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Compare the epidemiology, histologic subtypes, and clinical presentations of ovarian, endometrial, cervical, vulvar, and vaginal cancers
2. Apply FIGO staging systems for ovarian and endometrial cancer and correlate stage with treatment planning and prognosis
3. Describe the surgical principles of cytoreductive surgery for ovarian cancer and staging surgery for endometrial cancer including the role of sentinel lymph node mapping
4. Identify hereditary cancer syndromes including BRCA1/2 and Lynch syndrome and recommend appropriate genetic testing and risk-reducing interventions
5. Explain the roles of chemotherapy, radiation therapy, immunotherapy, and targeted agents including PARP inhibitors in the treatment of gynecologic malignancies
6. Counsel patients on cancer survivorship issues including surveillance protocols, late treatment effects, fertility preservation, and integration of palliative care

Seminar Outline

Section 1: Overview of Gynecologic Cancers

Gynecologic cancers collectively account for a significant proportion of cancer incidence and mortality among women, with distinct epidemiologic profiles, risk factors, and clinical behaviors for each primary site. Endometrial cancer is the most common gynecologic malignancy in the developed world, with rising incidence driven largely by the obesity epidemic, and is characterized by relatively favorable overall survival because the majority of cases present at an early stage. Ovarian cancer, while the second most common gynecologic cancer, carries the highest mortality rate due to the absence of effective screening and the advanced stage at which most patients are diagnosed. Cervical cancer, the third most common gynecologic malignancy in developed nations but the leading gynecologic cancer in low-resource settings, is uniquely preventable through HPV vaccination and cervical screening programs. Vulvar cancer accounts for approximately 4 percent of gynecologic cancers, and vaginal cancer is the rarest at 1 to 2 percent.

Risk factors for gynecologic cancers differ substantially by primary site, reflecting distinct pathogenic mechanisms. Endometrial cancer is driven primarily by chronic unopposed estrogen exposure, with obesity as the dominant risk factor through peripheral aromatization of androgens to estrogens in adipose tissue. Ovarian cancer risk is strongly influenced by genetic factors, with BRCA1 and BRCA2 mutations conferring the highest heritable risk, while protective factors include oral contraceptive use, multiparity, and breastfeeding, all of which suppress ovulation. Cervical cancer is caused by persistent high-risk HPV infection, with smoking, immunosuppression, and multiple sexual partners as co-factors. Vulvar cancer follows two distinct pathogenic pathways, one HPV-related affecting younger women and one associated with chronic vulvar dermatoses such as lichen sclerosus in older women. Understanding these risk factor profiles guides cancer prevention strategies and targeted screening.

Prevention strategies for gynecologic cancers represent some of the most effective cancer prevention interventions in all of oncology. HPV vaccination prevents the vast majority of cervical cancers as well as HPV-related vulvar and vaginal cancers, and cervical screening with Pap smear and HPV testing detects preinvasive lesions that can be treated before cancer develops. Risk-reducing salpingo-oophorectomy in BRCA carriers eliminates the ovarian cancer risk and is the single most effective intervention for this high-risk population. Combined oral contraceptive use reduces ovarian cancer risk by 40 to 50 percent and endometrial cancer risk by 50 percent with prolonged use. Weight management and treatment of chronic anovulation reduce endometrial cancer risk by addressing the pathogenic mechanism of unopposed estrogen. Opportunistic salpingectomy at the time of benign gynecologic or obstetric surgery is increasingly advocated based on evidence that many high-grade serous ovarian cancers originate in the fallopian tube.

The clinical approach to a patient with suspected gynecologic malignancy begins with a comprehensive history eliciting presenting symptoms, which may include abnormal vaginal bleeding, pelvic pain, abdominal distension, change in bowel or bladder habits, and weight loss. Physical examination includes complete abdominal examination for masses and ascites, speculum examination for visible cervical or vaginal lesions, and bimanual and rectovaginal examination to assess the uterus, adnexa, parametria, and cul-de-sac. Imaging modalities play an essential role, with transvaginal ultrasonography as the initial study for pelvic masses and endometrial evaluation, CT of the chest, abdomen, and pelvis for staging, MRI for pelvic soft tissue delineation particularly in cervical cancer, and PET-CT for detecting distant metastatic disease. Tissue diagnosis through biopsy is paramount, and referral to a gynecologic oncologist is recommended for any suspected gynecologic malignancy, as surgeon specialty has been shown to impact outcomes, particularly in ovarian cancer.

<image>Panel A: Comparative bar graph of gynecologic cancer incidence showing endometrial cancer as most common, followed by ovarian, cervical, vulvar, and vaginal cancer, with five-year survival rates overlaid for each type. Panel B: Risk factor matrix showing the major risk factors for each gynecologic cancer type with arrows indicating strength of association and color-coded by modifiable versus non-modifiable factors. Panel C: Prevention strategy diagram mapping HPV vaccination, cervical screening, RRSO, OCP use, weight management, and opportunistic salpingectomy to their respective target cancers. Panel D: Clinical evaluation pathway showing history, physical examination, imaging modalities, tissue biopsy, and referral decision points for suspected gynecologic malignancy.</image>

Section 2: Ovarian Cancer Epidemiology and Presentation

Ovarian cancer is the most lethal gynecologic malignancy, with approximately 70 percent of patients diagnosed at advanced stage (III or IV) due to the absence of an effective screening test and the nonspecific nature of early symptoms. The peak incidence occurs in women aged 55 to 65 years, and the overall five-year survival rate is only 30 to 50 percent across all stages, though early-stage disease has a markedly better prognosis with five-year survival exceeding 90 percent for stage IA. The incidence has been gradually declining in the developed world, attributed to widespread use of oral contraceptives and increasing rates of salpingectomy. Despite decades of investigation, neither CA-125 serum testing nor transvaginal ultrasonography has been validated as effective population-based screening tools, as they lack sufficient sensitivity and specificity to reduce mortality without causing substantial harm from false-positive results and unnecessary surgery.

The histologic classification of ovarian cancer has undergone significant revision with the recognition that ovarian epithelial cancers are not a single entity but rather a heterogeneous group of diseases with distinct origins, molecular profiles, and clinical behaviors. High-grade serous carcinoma is the most common subtype, accounting for approximately 70 percent of ovarian cancers, and is now understood to originate predominantly from the fimbrial epithelium of the fallopian tube rather than the ovarian surface epithelium. Endometrioid carcinoma (10 percent) and clear cell carcinoma (10 percent) are both associated with endometriosis and may arise through malignant transformation of endometriotic implants. Mucinous carcinoma (3 percent) is often stage I at diagnosis and must be distinguished from metastatic gastrointestinal primaries. Low-grade serous carcinoma is a distinct entity from high-grade serous, with indolent behavior, BRAF and KRAS mutations rather than TP53 mutations, and relative chemoresistance.

The clinical presentation of ovarian cancer is notoriously insidious, with symptoms that are common and easily attributed to benign conditions, leading to diagnostic delay. The most frequently reported symptoms are persistent abdominal bloating or increased abdominal girth, pelvic or abdominal pain, difficulty eating or early satiety, and urinary urgency or frequency. These symptoms are significant when they are new in onset, occur nearly daily, and persist for more than 2 to 3 weeks. Ascites is often the presenting finding in advanced disease, causing progressive abdominal distension, discomfort, and respiratory compromise from diaphragmatic splinting. Pleural effusions, particularly right-sided, occur in stage IV disease. Less common presentations include bowel obstruction, venous thromboembolism, and new-onset ovarian mass in a postmenopausal woman.

The FIGO staging system for ovarian cancer is based on surgical findings, reflecting the critical role of surgical exploration in determining disease extent. Stage I disease is confined to the ovaries, subdivided by unilateral versus bilateral involvement and the presence of capsule rupture or surface involvement. Stage II indicates pelvic extension to the uterus, fallopian tubes, or other pelvic tissues. Stage III encompasses peritoneal spread beyond the pelvis or retroperitoneal lymph node involvement, with substage IIIC indicating peritoneal implants greater than 2 centimeters in greatest dimension or positive retroperitoneal nodes. Stage IV represents distant metastases, including malignant pleural effusion (IVA) or parenchymal metastases to the liver, spleen, or extra-abdominal sites (IVB). The prognostic significance of staging is profound, with five-year survival ranging from greater than 90 percent for stage IA to less than 20 percent for stage IV.

<image>Panel A: Pie chart of ovarian cancer histologic subtypes showing high-grade serous (70 percent), endometrioid (10 percent), clear cell (10 percent), mucinous (3 percent), low-grade serous (rare), and other (rare) with molecular features of each type. Panel B: Symptom awareness graphic showing the four cardinal symptoms of ovarian cancer (bloating, pelvic/abdominal pain, difficulty eating/early satiety, urinary symptoms) with the threshold of daily occurrence for more than 2 to 3 weeks prompting evaluation. Panel C: CT image of the abdomen and pelvis demonstrating advanced ovarian cancer with a large pelvic mass, ascites, omental caking, and peritoneal implants. Panel D: FIGO staging diagram for ovarian cancer illustrating stages I through IV with anatomic representations of disease extent and corresponding five-year survival rates.</image>

Section 3: Ovarian Cancer Management

The diagnostic evaluation of a suspected ovarian malignancy involves a combination of imaging, serum markers, and surgical exploration, with emphasis on avoiding percutaneous biopsy of intact ovarian masses due to the risk of peritoneal seeding and upstaging. Transvaginal and transabdominal ultrasonography is the initial imaging modality, assessing the morphologic features of the adnexal mass including size, solid components, septations, papillary projections, and associated ascites. CT of the chest, abdomen, and pelvis is performed for staging to evaluate for peritoneal carcinomatosis, omental involvement, lymphadenopathy, and distant metastases. Serum CA-125 is elevated in approximately 80 percent of advanced epithelial ovarian cancers and is useful for monitoring treatment response and detecting recurrence, though it lacks specificity for screening purposes as it is also elevated in endometriosis, PID, liver disease, and other benign conditions. When tissue diagnosis is necessary before definitive surgery, paracentesis of ascitic fluid for cytology or image-guided biopsy of accessible metastatic deposits is preferred over ovarian biopsy.

Surgical management is the cornerstone of ovarian cancer treatment and serves both diagnostic and therapeutic purposes. Comprehensive surgical staging for apparent early-stage disease includes total abdominal hysterectomy with bilateral salpingo-oophorectomy, omentectomy, pelvic and para-aortic lymph node dissection, peritoneal biopsies from multiple sites, and collection of peritoneal washings for cytology. For advanced-stage disease, the primary goal of surgery is maximal cytoreduction, defined as the removal of all visible tumor with the objective of achieving no gross residual disease, as the volume of residual disease after primary surgery is the most important prognostic factor after stage. Optimal debulking with no visible residual disease is associated with significantly improved progression-free and overall survival. Fertility-sparing surgery with unilateral salpingo-oophorectomy and comprehensive staging may be offered to selected young women with apparent stage IA, grade 1 disease of favorable histology.

Chemotherapy is an essential component of ovarian cancer treatment for all patients beyond the lowest-risk early-stage disease. The standard first-line chemotherapy regimen is carboplatin (area under the curve 5 to 6) plus paclitaxel (175 mg/m2) administered intravenously every 3 weeks for 6 cycles. For patients with advanced disease who are not suitable candidates for primary cytoreductive surgery due to extent of disease or medical comorbidities, neoadjuvant chemotherapy with 3 to 4 cycles of carboplatin/paclitaxel followed by interval debulking surgery and completion of chemotherapy has been shown to achieve similar overall survival with lower surgical morbidity. Intraperitoneal chemotherapy, which delivers high drug concentrations directly to the peritoneal surfaces, has shown survival benefit in select patients with optimally debulked stage III disease, though its use is complicated by catheter-related complications and toxicity.

Targeted therapy and maintenance strategies have transformed the management of advanced ovarian cancer. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, is approved for addition to first-line chemotherapy and as maintenance therapy in advanced-stage disease, and has demonstrated improvement in progression-free survival. PARP inhibitors, including olaparib, niraparib, and rucaparib, represent the most significant therapeutic advance, exploiting the concept of synthetic lethality in tumors with homologous recombination deficiency, particularly those with BRCA1/2 mutations. Olaparib maintenance therapy following response to platinum-based chemotherapy in BRCA-mutated ovarian cancer has demonstrated dramatic improvements in progression-free survival. For recurrent disease, treatment decisions are guided by the platinum-free interval, with platinum-sensitive recurrence (more than 6 months since last platinum treatment) treated with platinum-based rechallenge and platinum-resistant recurrence treated with non-platinum agents such as liposomal doxorubicin, gemcitabine, or topotecan.

<image>Panel A: Surgical photograph of optimal cytoreductive surgery for advanced ovarian cancer showing the pelvis after total abdominal hysterectomy, bilateral salpingo-oophorectomy, and removal of peritoneal implants with no visible residual tumor. Panel B: Diagram of the PARP inhibitor mechanism of synthetic lethality showing how BRCA-mutated tumor cells with defective homologous recombination are selectively killed when PARP-mediated repair is blocked, while normal cells with intact BRCA function survive. Panel C: Treatment algorithm for newly diagnosed ovarian cancer showing pathways for primary cytoreduction versus neoadjuvant chemotherapy based on resectability assessment, followed by adjuvant chemotherapy and maintenance therapy decisions. Panel D: Graph of progression-free survival from PARP inhibitor maintenance trials showing the dramatic separation of curves between olaparib and placebo groups in BRCA-mutated patients.</image>

Section 4: Endometrial Cancer Epidemiology and Classification

Endometrial cancer is the most common gynecologic malignancy in the United States and other developed nations, with approximately 65,000 new cases diagnosed annually, and its incidence is rising in parallel with increasing rates of obesity. The peak incidence occurs in women aged 60 to 70 years, though younger women with risk factors such as polycystic ovary syndrome, obesity, or chronic anovulation may also develop this cancer. The overall prognosis is relatively favorable compared with other gynecologic cancers, with a five-year survival rate exceeding 80 percent, because the majority of patients present with postmenopausal bleeding that prompts early evaluation and diagnosis at an early, curable stage. However, certain high-risk histologic subtypes carry a much poorer prognosis, and the mortality rate has been increasing despite the overall favorable survival statistics, partly due to the rising proportion of aggressive subtypes and the impact of obesity-related comorbidities.

The molecular classification of endometrial cancer has increasingly supplanted the traditional dualistic model, but the clinical distinction between Type I and Type II tumors remains useful. Type I endometrial cancers, comprising approximately 80 percent of cases, are endometrioid in histology, estrogen-driven, typically low-grade, associated with obesity and hyperplasia, and carry a favorable prognosis. Type II endometrial cancers, accounting for approximately 20 percent, include serous, clear cell, and carcinosarcoma (malignant mixed Mullerian tumor) histologies that are not estrogen-dependent, occur in older, often thinner women, tend to present at advanced stage with extrauterine spread, and have significantly worse survival rates even when diagnosed at early stage. The molecular classification system, incorporating POLE ultramutated, microsatellite instability-high, copy number low, and copy number high categories, provides more precise prognostic information and is increasingly integrated into treatment planning.

Risk factors for Type I endometrioid endometrial cancer center on chronic exposure to estrogen unopposed by progesterone. Obesity is the dominant risk factor, with each 5 kg/m2 increase in body mass index increasing endometrial cancer risk by approximately 50 percent through peripheral aromatization of androgens to estrogen in adipose tissue. Polycystic ovary syndrome and chronic anovulation expose the endometrium to continuous estrogen without the differentiating and antiproliferative effects of progesterone produced after ovulation. Tamoxifen, used in breast cancer treatment, exerts estrogen agonist effects on the endometrium, increasing endometrial cancer risk 2- to 7-fold. Nulliparity, late menopause, and diabetes mellitus are additional risk factors. Estrogen-only hormone replacement therapy without progestogen in women with a uterus increases risk, which is why combined estrogen-progestogen therapy is mandatory for women with an intact uterus. Protective factors include combined oral contraceptive use, progesterone-containing IUDs, multiparity, and physical activity.

The clinical presentation of endometrial cancer is characterized by abnormal uterine bleeding, which is present in approximately 90 percent of cases. In postmenopausal women, any vaginal bleeding should be considered endometrial cancer until proven otherwise, though benign etiologies such as atrophic endometrium and polyps are far more common. Premenopausal women may present with heavy, prolonged, or irregular menstrual bleeding. Less common presentations include pyometra from cervical stenosis obstructing drainage of uterine fluid, incidental discovery of endometrial thickening on imaging obtained for other indications, and abnormal glandular cells on Pap smear. The diagnosis is established by endometrial tissue sampling, most commonly through office endometrial biopsy using a Pipelle device, which has a sensitivity of approximately 90 to 95 percent for detecting endometrial cancer. Transvaginal ultrasonography demonstrating an endometrial thickness of 4 millimeters or less in a postmenopausal woman has a high negative predictive value, though biopsy is preferred when clinical suspicion is high.

<image>Panel A: Graph of endometrial cancer incidence trends over the past three decades showing the rising incidence correlated with increasing obesity prevalence in the population. Panel B: Comparison diagram of Type I versus Type II endometrial cancer showing differences in histology, molecular features, patient demographics, risk factors, typical stage at diagnosis, and five-year survival rates. Panel C: Risk factor web diagram for Type I endometrial cancer centered on unopposed estrogen with radiating connections to obesity, PCOS, anovulation, tamoxifen, nulliparity, late menopause, and diabetes with corresponding relative risk magnitudes. Panel D: Endometrial biopsy technique illustration showing the Pipelle device inserted through the cervical os into the endometrial cavity with accompanying TVUS image of thickened endometrium exceeding 4 millimeters in a postmenopausal woman.</image>

Section 5: Endometrial Cancer Staging and Treatment

The diagnosis of endometrial cancer prompts a systematic staging evaluation beginning with cross-sectional imaging. Endometrial biopsy with a Pipelle device is the first-line diagnostic procedure and provides histologic type and grade. When office biopsy is inadequate or nondiagnostic, dilation and curettage, often with hysteroscopic visualization, provides more comprehensive sampling. Transvaginal ultrasound assesses endometrial thickness and myometrial invasion depth, while contrast-enhanced MRI of the pelvis provides the most accurate preoperative assessment of myometrial invasion, cervical stromal extension, and lymph node involvement. CT of the chest and abdomen is performed for higher-grade and aggressive histologies to evaluate for distant metastatic disease. Serum CA-125 may be elevated in advanced endometrial cancer and can be useful for monitoring, though it is not a diagnostic test.

The FIGO staging system for endometrial cancer is surgically based and directly influences treatment decisions. Stage IA disease involves tumor confined to the endometrium or with less than 50 percent myometrial invasion, while stage IB indicates 50 percent or greater myometrial invasion. Stage II disease involves cervical stromal invasion, as opposed to mere endocervical glandular involvement, which does not upstage. Stage III encompasses spread to the uterine serosa, adnexa, vagina, or pelvic and para-aortic lymph nodes, with substages IIIA through IIIC1/C2 providing additional prognostic refinement. Stage IV includes invasion of the bladder or bowel mucosa (IVA) or distant metastases including intra-abdominal spread or inguinal lymph nodes (IVB). The depth of myometrial invasion is a critical prognostic factor, as it correlates with the likelihood of lymph node metastasis, extrauterine spread, and recurrence.

Surgical treatment is the primary modality for endometrial cancer and consists of total hysterectomy with bilateral salpingo-oophorectomy, with lymph node assessment for staging. Minimally invasive surgery by laparoscopy or robotic-assisted approach is the preferred surgical technique, as randomized trials have demonstrated equivalent oncologic outcomes with reduced morbidity, shorter hospital stay, and faster recovery compared with open laparotomy. Sentinel lymph node mapping has emerged as the standard approach for lymph node assessment, replacing complete pelvic and para-aortic lymphadenectomy for most patients, as it provides accurate staging information with significantly less surgical morbidity including reduction in lower extremity lymphedema. Peritoneal washings are collected for cytology, though positive cytology alone no longer alters the FIGO stage. For young women with grade 1 endometrioid adenocarcinoma confined to the endometrium who desire future fertility, conservative management with high-dose progestin therapy and close surveillance is an option, though it requires extensive counseling regarding the risk of persistent or progressive disease.

Adjuvant therapy following surgery is determined by risk stratification based on stage, grade, histologic subtype, and the presence of lymphovascular space invasion. Low-risk patients with stage IA, grade 1 or 2 endometrioid cancer require no adjuvant therapy, as their recurrence risk is less than 5 percent. Intermediate-risk patients may benefit from vaginal cuff brachytherapy alone, which reduces local recurrence without the side effects of external beam radiation. High-intermediate and high-risk patients, including those with deep myometrial invasion, grade 3 tumors, or lymphovascular space invasion, receive combination external beam pelvic radiation with or without chemotherapy. Patients with aggressive histologies including serous, clear cell, and carcinosarcoma, as well as those with stage III or IV disease, typically receive systemic chemotherapy with carboplatin and paclitaxel, often combined with radiation therapy. The combination of lenvatinib plus pembrolizumab has demonstrated significant activity in advanced, recurrent endometrial cancer that is not microsatellite instability-high, while pembrolizumab alone is active in MSI-high/dMMR tumors.

<image>Panel A: FIGO staging diagram for endometrial cancer showing cross-sectional views of the uterus illustrating stage IA (less than 50 percent myometrial invasion), IB (50 percent or greater), II (cervical stromal invasion), III (spread to serosa, adnexa, or nodes), and IV (bladder, bowel, or distant). Panel B: Intraoperative photograph of sentinel lymph node mapping during robotic-assisted hysterectomy showing fluorescent ICG-stained lymph node identified with near-infrared camera. Panel C: Adjuvant therapy decision algorithm stratified by risk category showing observation for low-risk, vaginal brachytherapy for intermediate-risk, and chemotherapy plus radiation for high-risk patients with specific criteria for each group. Panel D: Kaplan-Meier curves comparing progression-free survival for lenvatinib plus pembrolizumab versus chemotherapy in advanced endometrial cancer demonstrating the efficacy of this combination.</image>

Section 6: Cervical Cancer in the Oncology Context

Cervical cancer occupies a unique position among gynecologic malignancies as a cancer that is almost entirely preventable through vaccination and screening yet remains a leading cause of cancer death worldwide, particularly in low- and middle-income countries without established screening programs. Persistent infection with high-risk HPV types, predominantly types 16 and 18, is the necessary etiologic factor in virtually all cervical cancers. In screened populations, the incidence of cervical cancer has declined dramatically over the past 50 years, and countries with high HPV vaccination coverage are beginning to observe further reductions in both precancerous lesions and invasive cancer. Despite these advances, disparities in screening access and vaccination uptake mean that cervical cancer continues to disproportionately affect women of lower socioeconomic status, racial and ethnic minorities, and those in resource-limited settings.

The histologic classification of cervical cancer is dominated by squamous cell carcinoma, which accounts for 70 to 80 percent of cases and arises from the squamocolumnar junction at the transformation zone. Adenocarcinoma comprises 20 to 25 percent of cases and originates from the endocervical glandular epithelium, with its relative proportion increasing in recent decades, possibly because glandular precursors are less reliably detected by cytologic screening. Adenosquamous carcinoma contains both squamous and glandular elements. Small cell neuroendocrine carcinoma of the cervix is rare but highly aggressive, with behavior similar to small cell lung cancer and requiring a chemotherapy-based treatment approach. Molecular subtypes are being increasingly characterized, with implications for immunotherapy responsiveness and targeted therapy selection.

The 2018 FIGO staging system for cervical cancer is the only gynecologic cancer staging system that is primarily clinical, though it now permits incorporation of imaging and pathologic findings including lymph node status. Stage IA disease is microscopic, subdivided by depth of invasion, with IA1 representing invasion of 3 millimeters or less and IA2 indicating invasion between 3 and 5 millimeters. Stage IB encompasses visible tumors or those exceeding 5 millimeters depth, with further subdivision by size into IB1 (up to 2 cm), IB2 (2 to 4 cm), and IB3 (greater than 4 cm). Stage II extends beyond the cervix, with IIA involving the upper two-thirds of the vagina and IIB indicating parametrial involvement. Stage IIIA involves the lower third of the vagina, IIIB extends to the pelvic sidewall or causes hydronephrosis, and IIIC1/C2 indicates pelvic or para-aortic lymph node involvement, respectively. Stage IV encompasses bladder or rectal mucosal invasion (IVA) or distant metastases (IVB).

Treatment of cervical cancer is determined by stage, with a fundamental division between early-stage disease amenable to surgical management and locally advanced disease requiring chemoradiation. Stage IA1 without lymphovascular space invasion can be managed with cone biopsy alone or simple hysterectomy. Stage IA2 through IB2 disease is treated with radical hysterectomy and bilateral pelvic lymphadenectomy, or alternatively with primary chemoradiation, as both modalities provide equivalent survival. The sentinel lymph node concept is being validated for early-stage cervical cancer to reduce lymphadenectomy morbidity. For locally advanced disease from stage IB3 through IVA, primary chemoradiation with weekly cisplatin as a radiosensitizer plus external beam radiation and intracavitary brachytherapy is the standard of care. Importantly, surgery after primary chemoradiation is avoided because the combination of both modalities increases morbidity without survival benefit. Cisplatin at 40 mg/m2 weekly during radiation has been conclusively shown to improve survival compared with radiation alone. For recurrent or metastatic cervical cancer, pembrolizumab has demonstrated activity in PD-L1-positive tumors, and the combination of pembrolizumab with chemotherapy and bevacizumab has become a new standard of care for first-line treatment of persistent, recurrent, or metastatic disease.

<image>Panel A: Schematic of cervical cancer FIGO staging from IA through IVB with corresponding anatomic diagrams showing progressive tumor extension from microscopic invasion through parametrial involvement to distant spread. Panel B: Treatment decision algorithm for cervical cancer showing surgical management for early-stage disease (IA1 through IB2) and primary chemoradiation for locally advanced disease (IB3 through IVA) with fertility-sparing options annotated. Panel C: Diagram of brachytherapy tandem and ovoid placement within the uterus and vagina for cervical cancer treatment showing the radiation dose distribution to tumor and surrounding normal tissues. Panel D: Forest plot from clinical trials showing the survival benefit of adding cisplatin to radiation therapy for locally advanced cervical cancer across multiple randomized studies.</image>

Section 7: Vulvar and Vaginal Cancer

Vulvar cancer is an uncommon but clinically important gynecologic malignancy that accounts for approximately 4 percent of gynecologic cancers, with the peak incidence in the seventh and eighth decades of life. Squamous cell carcinoma is the dominant histologic type, comprising approximately 90 percent of cases, with two recognized pathogenic pathways: the HPV-related pathway affecting younger women through usual-type vulvar intraepithelial neoplasia, and the non-HPV pathway affecting older women through differentiated VIN arising in the setting of chronic lichen sclerosus. The HPV-related pathway tends to produce basaloid or warty squamous cell carcinomas with better prognosis, while the lichen sclerosus pathway produces keratinizing squamous cell carcinomas with a higher propensity for local recurrence and nodal metastasis. Less common vulvar malignancies include melanoma, which accounts for approximately 5 percent of vulvar cancers and requires different staging and management, Bartholin gland carcinoma, basal cell carcinoma, and sarcoma.

The clinical presentation of vulvar cancer frequently involves a visible or palpable mass, ulcer, or growth on the vulva, most commonly located on the labia majora. Many patients report a prolonged history of vulvar pruritus, burning, or pain that may have been attributed to benign vulvar conditions for months or years before the diagnosis is established, highlighting the importance of biopsy for any persistent or suspicious vulvar lesion. The FIGO staging system for vulvar cancer is surgically based, with stage I confined to the vulva (subdivided by depth of invasion), stage II extending to adjacent perineal structures, stage III involving inguinofemoral lymph nodes, and stage IV indicating invasion of the bladder, rectal mucosa, or pelvic bone, or distant metastases. Treatment of early-stage vulvar cancer consists of wide local excision or radical vulvectomy with a minimum of 1-centimeter surgical margins, combined with sentinel lymph node biopsy for tumors with more than 1 millimeter of stromal invasion. For advanced disease with positive lymph nodes, adjuvant radiation with or without chemotherapy is indicated, and primary chemoradiation is used for locally advanced tumors where exenterative surgery would be required.

Vaginal cancer is the rarest gynecologic malignancy, accounting for only 1 to 2 percent of gynecologic cancers, and is classified as a primary vaginal cancer only when the cervix and vulva are not involved, as secondary involvement by cervical or vulvar cancer is far more common. Squamous cell carcinoma is the predominant histologic type, and risk factors include HPV infection, prior cervical intraepithelial neoplasia, prior pelvic radiation, immunosuppression, and historically, in utero exposure to diethylstilbestrol, which was associated with clear cell adenocarcinoma of the vagina in young women exposed during fetal development. Patients typically present with painless vaginal bleeding, watery or blood-tinged discharge, or a palpable vaginal mass, and diagnosis requires biopsy of the lesion. Treatment is predominantly radiation-based using a combination of external beam radiation and intracavitary or interstitial brachytherapy, as the close anatomic proximity of the vagina to the bladder and rectum limits the role of radical surgery for most cases.

Diethylstilbestrol exposure deserves special mention for its historical importance and ongoing clinical relevance. Between the 1940s and 1971, DES, a synthetic estrogen, was prescribed to millions of pregnant women in the belief that it prevented miscarriage and pregnancy complications. In utero exposure was subsequently found to cause a rare but distinctive clear cell adenocarcinoma of the vagina and cervix in exposed daughters, with peak incidence at age 15 to 22. While the cohort of DES-exposed individuals has now passed the age of peak risk for DES-related clear cell carcinoma, these women remain at slightly elevated risk for cervical and vaginal squamous cell carcinoma throughout their lives and may have reproductive tract anomalies including T-shaped uterus, cervical hood, and vaginal adenosis. The DES experience remains a landmark lesson in the importance of long-term safety monitoring of medications used in pregnancy.

<image>Panel A: Clinical photograph of a vulvar squamous cell carcinoma showing an ulcerated, irregular mass on the labia majora in an elderly woman with surrounding areas of lichen sclerosus. Panel B: FIGO staging diagrams for vulvar cancer (stages I through IV) and vaginal cancer showing anatomic extent of disease at each stage with key prognostic features. Panel C: Sentinel lymph node mapping procedure during vulvar cancer surgery using blue dye and technetium-99m colloid injection showing the identified sentinel node in the inguinofemoral region. Panel D: Historical timeline of DES exposure showing the period of use (1940s to 1971), identification of DES-related clear cell adenocarcinoma (1971), and long-term health effects in exposed daughters including vaginal adenosis, reproductive tract anomalies, and cancer risk.</image>

Section 8: Hereditary Cancer Syndromes

BRCA1 and BRCA2 are tumor suppressor genes encoding proteins essential for DNA double-strand break repair through homologous recombination, and germline mutations in these genes confer dramatically elevated lifetime risks of both breast and ovarian cancer. Women with BRCA1 mutations carry a 35 to 45 percent lifetime risk of ovarian cancer and a 60 to 80 percent lifetime risk of breast cancer, while BRCA2 mutations confer a 15 to 25 percent lifetime risk of ovarian cancer and a 45 to 70 percent lifetime risk of breast cancer. BRCA1-associated ovarian cancers are predominantly high-grade serous histology and tend to occur at younger ages (median 50 years) compared with BRCA2 (median 60 years). Both mutations are inherited in an autosomal dominant pattern with variable penetrance. Certain populations carry founder mutations at higher frequency, most notably Ashkenazi Jewish individuals, among whom approximately 1 in 40 carry one of three specific BRCA1/2 mutations compared with the general population prevalence of approximately 1 in 300 to 500.

Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is caused by germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is the most common heritable cause of endometrial cancer. Women with Lynch syndrome carry a 40 to 60 percent lifetime risk of endometrial cancer, a 10 to 15 percent lifetime risk of ovarian cancer, and a 40 to 80 percent lifetime risk of colorectal cancer, among other malignancies. Endometrial cancer is frequently the sentinel cancer in women with Lynch syndrome, presenting before colorectal cancer in approximately 50 percent of affected women. The molecular hallmark of Lynch syndrome tumors is microsatellite instability and loss of mismatch repair protein expression on immunohistochemistry, which can be identified on tumor tissue testing and should prompt germline genetic evaluation. Universal tumor testing for mismatch repair deficiency in all newly diagnosed endometrial cancers is now recommended to identify Lynch syndrome carriers and their at-risk family members.

Referral for genetic counseling and testing should be considered in patients with clinical features suggestive of hereditary cancer predisposition. Key indicators include a family history of multiple affected relatives with breast, ovarian, endometrial, or colorectal cancer, young age at cancer diagnosis (particularly breast cancer before age 50 or ovarian cancer at any age), specific histologic features such as high-grade serous ovarian cancer or triple-negative breast cancer, Ashkenazi Jewish ancestry, a personal history of multiple primary cancers, and male breast cancer in the family. Testing has expanded from single-gene analysis to multi-gene panel testing that simultaneously evaluates numerous cancer susceptibility genes, increasing the yield of clinically actionable findings but also generating variants of uncertain significance that require careful interpretation and counseling. Genetic counseling before and after testing is essential to ensure informed consent, appropriate test selection, and accurate interpretation and communication of results.

Risk-reducing surgical interventions are the most effective cancer prevention strategies for carriers of high-penetrance cancer susceptibility genes. Risk-reducing salpingo-oophorectomy is recommended for BRCA1 carriers at age 35 to 40 and for BRCA2 carriers at age 40 to 45, after completion of childbearing. This procedure reduces ovarian cancer risk by approximately 80 percent and breast cancer risk by approximately 50 percent through elimination of ovarian estrogen production. The removed specimens must be thoroughly sectioned and examined pathologically using the SEE-FIM (Sectioning and Extensively Examining the FIMbria) protocol to detect occult tubal or ovarian carcinoma, which is found in 2 to 10 percent of RRSO specimens. For Lynch syndrome, prophylactic hysterectomy with bilateral salpingo-oophorectomy is recommended after completion of childbearing, eliminating the risk of both endometrial and ovarian cancer. Opportunistic salpingectomy at the time of benign gynecologic or cesarean delivery surgery is increasingly being offered to all women as a potential strategy for ovarian cancer risk reduction based on the tubal origin hypothesis.

<image>Panel A: Pedigree diagram of a family with BRCA1 mutation showing autosomal dominant inheritance pattern with affected members developing breast and ovarian cancer at young ages across multiple generations. Panel B: Diagram comparing the cancer risk spectrum of BRCA1, BRCA2, and Lynch syndrome showing lifetime risks of breast, ovarian, endometrial, and colorectal cancer for each syndrome with recommended surveillance and risk-reducing interventions. Panel C: Immunohistochemistry images showing loss of MLH1 and PMS2 expression in a Lynch syndrome-associated endometrial cancer compared with intact expression in a sporadic tumor. Panel D: Surgical specimen from risk-reducing salpingo-oophorectomy with SEE-FIM protocol showing serial cross-sectioning of the fallopian tube fimbria for microscopic examination to detect occult serous tubal intraepithelial carcinoma.</image>

Section 9: Treatment Modalities in Gynecologic Oncology

Surgical management in gynecologic oncology encompasses a spectrum from organ-preserving procedures in early-stage disease to ultraradical resections for advanced malignancies. The fundamental surgical principles include accurate staging through systematic assessment of disease extent, maximal cytoreduction to remove all visible tumor when cure is the intent, and minimally invasive approaches when oncologically equivalent to open surgery. Minimally invasive techniques including laparoscopy and robotic-assisted surgery have been validated for early-stage endometrial cancer and are widely adopted, offering patients shorter hospital stays, less blood loss, and faster recovery. Sentinel lymph node mapping has transformed lymph node assessment across gynecologic cancers, reducing the morbidity of complete lymphadenectomy while maintaining staging accuracy. Fertility-sparing surgical approaches are available for selected patients with early-stage ovarian, endometrial, and cervical cancer, requiring careful patient selection, extensive counseling, and close surveillance.

Radiation therapy plays a central role in the treatment of several gynecologic cancers, delivered through external beam radiation, brachytherapy, or both. External beam radiation therapy uses high-energy photons to treat the primary tumor and regional lymph node basins, with intensity-modulated radiation therapy allowing precise dose delivery while minimizing exposure to adjacent normal tissues including the small bowel, bladder, and rectum. Brachytherapy involves placement of radioactive sources directly into or adjacent to the tumor, providing a high radiation dose to the target volume with rapid dose fall-off to surrounding tissues. In cervical cancer, intracavitary brachytherapy with a tandem and ovoids or ring applicator is an essential component of treatment, delivering a boost dose to the cervical tumor. Vaginal cuff brachytherapy is used as adjuvant treatment for intermediate-risk endometrial cancer, reducing vaginal cuff recurrence with minimal side effects. Radiation-related complications include acute effects such as diarrhea, cystitis, and skin changes, and late effects including bowel obstruction, fistula formation, vaginal stenosis, and radiation-induced secondary malignancies.

Systemic chemotherapy is a cornerstone of treatment for advanced and recurrent gynecologic cancers. The carboplatin-paclitaxel doublet is the standard first-line regimen for both ovarian and endometrial cancer, administered intravenously every 3 weeks for 6 cycles. In cervical cancer, cisplatin serves primarily as a radiosensitizer when combined with external beam radiation for locally advanced disease, while carboplatin-paclitaxel with or without bevacizumab is used for recurrent or metastatic cervical cancer. Dose-dense chemotherapy schedules and intraperitoneal delivery routes have been investigated for ovarian cancer with evidence of improved outcomes in selected populations. Chemotherapy side effects common to platinum-taxane regimens include myelosuppression with neutropenic fever risk, peripheral neuropathy, nephrotoxicity (cisplatin), ototoxicity, nausea and vomiting, alopecia, and fatigue, requiring vigilant toxicity monitoring and supportive care.

Immunotherapy and molecularly targeted agents have expanded treatment options across gynecologic cancers. Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is approved for microsatellite instability-high or mismatch repair-deficient tumors regardless of primary site, making it applicable to Lynch syndrome-associated endometrial cancers and a subset of ovarian and cervical cancers. The combination of lenvatinib, a multi-kinase inhibitor, with pembrolizumab is active in advanced endometrial cancer regardless of MSI status. Bevacizumab, targeting VEGF, is integrated into the treatment of advanced ovarian and cervical cancer. PARP inhibitors exploit synthetic lethality in homologous recombination-deficient tumors and are approved for maintenance therapy in ovarian cancer, with olaparib, niraparib, and rucaparib each having distinct indications based on BRCA mutation status and homologous recombination deficiency testing. Molecular tumor profiling, including assessment of BRCA status, MSI/MMR, PD-L1 expression, and tumor mutational burden, has become integral to treatment selection in gynecologic oncology.

<image>Panel A: Comparison of surgical approaches showing open laparotomy versus minimally invasive robotic-assisted hysterectomy for endometrial cancer staging with annotated port placement, surgical steps, and comparative outcomes data. Panel B: Radiation therapy planning images showing intensity-modulated external beam radiation treatment plan for cervical cancer with color-coded dose distribution to the target volume and dose-sparing of adjacent organs. Panel C: Diagram of the molecular targets and mechanisms of action for key agents in gynecologic oncology including pembrolizumab (PD-1), bevacizumab (VEGF), olaparib (PARP), and lenvatinib (multi-kinase) with their approved indications. Panel D: Molecular testing algorithm for gynecologic cancer showing the workflow from tumor biopsy through BRCA testing, MSI/MMR analysis, PD-L1 expression, and HRD testing to matched targeted therapy selection.</image>

Section 10: Survivorship and Palliative Care

Cancer surveillance following treatment for gynecologic malignancies is structured by cancer type and risk of recurrence, with the goal of detecting treatable recurrence while minimizing unnecessary testing and patient anxiety. Ovarian cancer surveillance typically includes clinical assessment with symptom review and physical examination combined with serum CA-125 measurement every 3 months for the first 2 years, every 6 months for years 3 to 5, and annually thereafter. Endometrial cancer follow-up involves clinical examination every 3 to 6 months for the first 2 to 3 years, then every 6 to 12 months, with imaging performed only for symptomatic patients rather than routinely. Cervical cancer surveillance includes pelvic examination with cytology every 3 to 6 months for the first 2 years, then every 6 to 12 months for the next 3 years. Imaging is generally reserved for patients with symptoms or rising tumor markers rather than performed at fixed intervals, as routine imaging-based surveillance has not been shown to improve overall survival in most gynecologic cancers.

Late effects of cancer treatment can significantly impact quality of life for gynecologic cancer survivors and require proactive management. Surgical menopause resulting from bilateral oophorectomy causes abrupt onset of vasomotor symptoms, genitourinary syndrome, mood changes, and accelerated bone loss, and hormone therapy may be appropriate for premenopausal women who undergo oophorectomy for non-hormone-dependent cancers. Pelvic radiation causes chronic changes to the bowel, bladder, and vagina, with late effects including radiation proctitis, radiation cystitis, vaginal stenosis, and sexual dysfunction. Regular use of vaginal dilators and topical estrogen following pelvic radiation helps maintain vaginal patency and function. Platinum-based chemotherapy can cause persistent peripheral neuropathy, ototoxicity, and nephrotoxicity. Lymphedema of the lower extremities following lymphadenectomy is a chronic condition requiring ongoing physical therapy, compression garments, and patient education, though its incidence is decreasing with the adoption of sentinel lymph node mapping.

Survivorship care extends beyond cancer surveillance to address the comprehensive health needs of cancer survivors. Sexual health is frequently impacted by gynecologic cancer treatment through surgical alteration of anatomy, vaginal stenosis from radiation, hormonal changes, and psychological factors, and should be proactively addressed through patient education, pelvic floor physical therapy, and referral to sexual health specialists when needed. Fertility considerations should be discussed before treatment begins for reproductive-age patients, with options including embryo or oocyte cryopreservation, fertility-sparing surgical approaches when oncologically safe, and reproductive endocrinology referral. Bone health is a priority for patients experiencing premature surgical menopause, requiring bone density monitoring and pharmacologic intervention when indicated. Cardiovascular risk monitoring is important for patients who received platinum-based chemotherapy or pelvic radiation, which can affect cardiac function and vascular health.

Palliative care should be integrated early in the disease trajectory for patients with advanced gynecologic cancers, beginning at the time of diagnosis rather than being reserved as an end-of-life intervention. Early palliative care has been shown to improve quality of life, reduce symptom burden, enhance patient understanding of prognosis, and in some studies, improve overall survival. Common symptoms requiring palliative management in gynecologic cancers include pain, which may be visceral from tumor mass effect or neuropathic from nerve compression or chemotherapy-induced neuropathy, nausea and vomiting, malignant ascites requiring periodic paracentesis or consideration of indwelling catheters, bowel obstruction, and malignant pleural effusions. Goals-of-care discussions should occur early and be revisited regularly, addressing the patient's values, preferences for treatment intensity, and advance directive planning. Hospice care is appropriate when curative or life-prolonging treatment is no longer beneficial or desired, providing symptom management, psychosocial support, and care coordination for the patient and family in the last phase of life.

<image>Panel A: Surveillance schedule timeline showing recommended examination intervals and tumor marker testing for ovarian, endometrial, and cervical cancer from treatment completion through 5 years, with annotations of when to obtain imaging. Panel B: Infographic of late treatment effects organized by treatment modality showing surgical effects (lymphedema, premature menopause, adhesions), radiation effects (bowel, bladder, vaginal stenosis), and chemotherapy effects (neuropathy, ototoxicity, early menopause). Panel C: Survivorship care model showing the interconnected domains of cancer surveillance, sexual health, fertility preservation, bone health, cardiovascular monitoring, psychosocial support, and preventive care for gynecologic cancer survivors. Panel D: Early palliative care integration model showing concurrent curative-intent treatment and palliative care from diagnosis through disease progression, transition to hospice, and bereavement support for the family.</image>

Summary

• Ovarian cancer carries the highest mortality among gynecologic cancers, with 70 percent diagnosed at advanced stage, and treatment centers on maximal cytoreductive surgery followed by carboplatin-paclitaxel chemotherapy
• High-grade serous carcinoma is the most common ovarian histology (70 percent), now understood to originate from the fallopian tube fimbria, and is frequently associated with BRCA mutations
• Endometrial cancer is the most common gynecologic malignancy, driven by obesity and unopposed estrogen, with five-year survival exceeding 80 percent when diagnosed at early stage
• Type I endometrial cancer (endometrioid, estrogen-related) carries better prognosis than Type II (serous, clear cell, carcinosarcoma), which is aggressive regardless of stage
• Cervical cancer is HPV-caused and preventable through vaccination and screening, with chemoradiation (cisplatin plus radiation) as the standard treatment for locally advanced disease
• Vulvar cancer follows two pathways: HPV-related (younger women) and lichen sclerosus-associated (older women), treated primarily with wide local excision and sentinel lymph node biopsy
• BRCA1 mutations confer 35 to 45 percent lifetime ovarian cancer risk, and risk-reducing salpingo-oophorectomy is recommended at age 35 to 40 for BRCA1 and 40 to 45 for BRCA2
• Lynch syndrome carries 40 to 60 percent lifetime endometrial cancer risk, and universal tumor MSI/MMR testing is recommended for all new endometrial cancers
• PARP inhibitors exploit synthetic lethality in BRCA-mutated ovarian cancer, providing dramatic improvements in progression-free survival as maintenance therapy
• Palliative care should be integrated early from diagnosis, with survivorship care addressing sexual health, fertility, bone health, and late treatment effects

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown